These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 2033429

  • 1. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial.
    Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracey J, Mills J, Volberding PA.
    J Clin Oncol; 1991 Jun; 9(6):929-40. PubMed ID: 2033429
    [Abstract] [Full Text] [Related]

  • 2. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C.
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [Abstract] [Full Text] [Related]

  • 3. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, Herndier B, Northfelt DW, Huang J, Tulpule A, Levine AM.
    N Engl J Med; 1997 Jun 05; 336(23):1641-8. PubMed ID: 9171066
    [Abstract] [Full Text] [Related]

  • 4. Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
    Hernàndez DE, Hernàndez AE.
    Eur J Cancer Care (Engl); 2006 Dec 05; 15(5):493-6. PubMed ID: 17177909
    [Abstract] [Full Text] [Related]

  • 5. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
    Bergmann L, Karakas T, Knuth A, Lautenschläger G, Mitrou PS, Hoelzer D.
    Eur J Cancer; 1995 Dec 05; 31A(13-14):2164-8. PubMed ID: 8652236
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
    Sawada KI, Sato N, Kohno M, Hannda H, Yasukouchi T, Tanngo M, Hirayama A, Koike T.
    Leuk Lymphoma; 1995 Dec 05; 20(1-2):103-9. PubMed ID: 8750630
    [Abstract] [Full Text] [Related]

  • 7. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
    Patte C, Laplanche A, Bertozzi AI, Baruchel A, Frappaz D, Schmitt C, Mechinaud F, Nelken B, Boutard P, Michon J.
    J Clin Oncol; 2002 Jan 15; 20(2):441-8. PubMed ID: 11786572
    [Abstract] [Full Text] [Related]

  • 8. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
    Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, Straus D, AIDS Malignancy Consortium.
    J Clin Oncol; 2001 Apr 15; 19(8):2171-8. PubMed ID: 11304769
    [Abstract] [Full Text] [Related]

  • 9. A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas.
    Hovgaard D, Nissen NI.
    Leuk Lymphoma; 1992 Jun 15; 7(3):217-24. PubMed ID: 1477649
    [Abstract] [Full Text] [Related]

  • 10. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
    Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, Kaiser G.
    J Clin Oncol; 1994 Dec 15; 12(12):2667-76. PubMed ID: 7989942
    [Abstract] [Full Text] [Related]

  • 11. Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.
    Engelhard M, Gerhartz H, Brittinger G, Engert A, Fuchs R, Geiseler B, Gerhartz D, Haunauske AR, Hartlapp HJ, Huhn D.
    Ann Oncol; 1994 Dec 15; 5 Suppl 2():123-5. PubMed ID: 7515644
    [Abstract] [Full Text] [Related]

  • 12. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
    Rossi G, Donisi A, Casari S, Re A, Stellini R, Cadeo G, Carosi G.
    Haematologica; 1998 Apr 15; 83(4):317-22. PubMed ID: 9592981
    [Abstract] [Full Text] [Related]

  • 13. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial.
    Kaku K, Takahashi M, Moriyama Y, Nakahata T, Masaoka T, Yoshida Y, Shibata A, Kaneko T, Miwa S.
    Leuk Lymphoma; 1993 Oct 15; 11(3-4):229-38. PubMed ID: 8260897
    [Abstract] [Full Text] [Related]

  • 14. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G.
    N Engl J Med; 1991 Jul 18; 325(3):164-70. PubMed ID: 1711156
    [Abstract] [Full Text] [Related]

  • 15. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
    Dotti G, Stella CC, Mangoni L, Cottafavi L, Caramatti C, Almici C, Rizzoli V.
    Haematologica; 1995 Jul 18; 80(2):142-5. PubMed ID: 7543069
    [Abstract] [Full Text] [Related]

  • 16. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
    Michel G, Landman-Parker J, Auclerc MF, Mathey C, Leblanc T, Legall E, Bordigoni P, Lamagnere JP, Demeocq F, Perel Y, Auvrignon A, Berthou C, Bauduer F, Pautard B, Schneider P, Schaison G, Leverger G, Baruchel A.
    J Clin Oncol; 2000 Apr 18; 18(7):1517-24. PubMed ID: 10735900
    [Abstract] [Full Text] [Related]

  • 17. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study.
    Hovgaard DJ, Nissen NI.
    J Clin Oncol; 1992 Mar 18; 10(3):390-7. PubMed ID: 1740678
    [Abstract] [Full Text] [Related]

  • 18. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
    Zagonel V, Babare R, Merola MC, Talamini R, Lazzarini R, Tirelli U, Carbone A, Monfardini S.
    Ann Oncol; 1994 Mar 18; 5 Suppl 2():127-32. PubMed ID: 7515645
    [Abstract] [Full Text] [Related]

  • 19. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.
    Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D.
    Blood; 1992 Sep 15; 80(6):1430-6. PubMed ID: 1381626
    [Abstract] [Full Text] [Related]

  • 20. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
    Tanosaki R, Okamoto S, Akatsuka N, Ishida A, Michikawa N, Masuda Y, Uchida H, Murata M, Kizaki M, Ikeda Y.
    Cancer; 1994 Oct 01; 74(7):1939-44. PubMed ID: 7521788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.